NCT02095873

Brief Summary

The purpose of this study is to determine whether dietary inducers of glyoxalase 1 are effective in improving metabolic and vascular health.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started May 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 18, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 26, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

March 6, 2017

Completed
Last Updated

March 6, 2017

Status Verified

January 1, 2017

Enrollment Period

9 months

First QC Date

March 18, 2014

Results QC Date

August 2, 2016

Last Update Submit

January 15, 2017

Conditions

Keywords

Oral glucose tolerance testFlow mediated dilatationAortal pulse wave velocityFinger-fold capillary density by capillaroscopy

Outcome Measures

Primary Outcomes (1)

  • Area Under the Curve for Oral Glucose Tolerance Test (oGGT)

    A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (\> 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.

    Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Secondary Outcomes (2)

  • Finger-fold Capillary Density by Capillaroscopy

    Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

  • Flow-mediated Dilatation (FMD)

    Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Other Outcomes (1)

  • Aortal Pulse Wave Velocity (aPWV)

    Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Study Arms (2)

Glo1-inducer then placebo

EXPERIMENTAL

Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).

Dietary Supplement: Glyoxalase 1 (Glo1) inducerDietary Supplement: Placebo

Placebo then Glo1-inducer

EXPERIMENTAL

Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).

Dietary Supplement: Glyoxalase 1 (Glo1) inducerDietary Supplement: Placebo

Interventions

Glyoxalase 1 (Glo1) inducerDIETARY_SUPPLEMENT

Dietary bioactive

Also known as: trans-resveratrol, 90 mg + hesperetin, 120 mg (combination)
Glo1-inducer then placeboPlacebo then Glo1-inducer
PlaceboDIETARY_SUPPLEMENT

Mannitol, 108 mg

Glo1-inducer then placeboPlacebo then Glo1-inducer

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI 25 - 40 kg/m2 (\>23 kg/m2 for Asians), with normal, impaired fasting or impaired postprandial glucose.
  • No other relevant morbidities.
  • Women will be preferably post-menopausal.

You may not qualify if:

  • Severe hypertriglyceridemia.
  • Uncontrolled hypertension, cardiovascular disease, relevant renal or hepatic disease, diabetes, and other relevant morbidity.
  • Excess alcohol consumption, smoking, acute pharmacological treatment with drugs affecting glucose metabolism such as steroids and antibiotics.
  • Anticoagulants.
  • Intake of herbal remedies.
  • Food allergies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Coventry & Warwickshire NHS Trust (UHCW)

Coventry, Warwickshire, CV22DX, United Kingdom

Location

Related Publications (3)

  • Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, Park BK, Souma T, Moriguchi T, Yamamoto M, Thornalley PJ. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J. 2012 Apr 1;443(1):213-22. doi: 10.1042/BJ20111648.

    PMID: 22188542BACKGROUND
  • Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun. 2015 Mar 6;458(2):221-6. doi: 10.1016/j.bbrc.2015.01.140. Epub 2015 Feb 7.

    PMID: 25666945BACKGROUND
  • Xue M, Weickert MO, Qureshi S, Kandala NB, Anwar A, Waldron M, Shafie A, Messenger D, Fowler M, Jenkins G, Rabbani N, Thornalley PJ. Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes. 2016 Aug;65(8):2282-94. doi: 10.2337/db16-0153. Epub 2016 May 11.

MeSH Terms

Conditions

Glucose IntoleranceAneurysm

Interventions

Lactoylglutathione LyaseResveratrolhesperetin

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Carbon-Sulfur LyasesLyasesEnzymesEnzymes and CoenzymesStilbestrolsStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolyphenolsPhenols

Results Point of Contact

Title
Paul J Thornalley
Organization
University of Warwick

Study Officials

  • Paul J Thornalley, BSc PhD

    University of Warwick

    STUDY CHAIR
  • Martin O Weickert, MD

    University Hospitals Coventry & Warwickshire NHS Trust

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 18, 2014

First Posted

March 26, 2014

Study Start

May 1, 2014

Primary Completion

February 1, 2015

Study Completion

May 1, 2015

Last Updated

March 6, 2017

Results First Posted

March 6, 2017

Record last verified: 2017-01

Data Sharing

IPD Sharing
Will share

Locations